Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q5039678> ?p ?o }
Showing triples 1 to 41 of
41
with 100 triples per page.
- Q5039678 subject Q18924462.
- Q5039678 subject Q5920511.
- Q5039678 subject Q7108202.
- Q5039678 subject Q8567712.
- Q5039678 subject Q8788974.
- Q5039678 subject Q8919936.
- Q5039678 abstract "Carisbamate (YKP 509, proposed trade name Comfyde) is an experimental anticonvulsant drug under development by Johnson & Johnson Pharmaceutical Research and Development. In 1998, the compound was in-licensed from SK Corp. (currently Life Science Business Division of SK Holdings), a South Korean company. A phase II clinical trial in the treatment of partial seizures demonstrated that the compound has efficacy in the treatment of partial seizures and a good safety profile. Since late 2006, the compound has been undergoing a large multicenter phase III clinical trial for the treatment of partial seizures. Its mechanism of action is unknown.On October 24, 2008, Johnson & Johnson announced that it had submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for carisbamate. Carisbamate has received provisional approval by the FDA to be marketed under the brand name of Comfyde. However, on August 21, 2009, Johnson & Johnson reported that the FDA had failed to give marketing approval.A double-blind, placebo-controlled trial cf carisbamate in 323 patients with migraine failed to demonstrate that the active drug was more effective than placebo. However, carisbamate was well tolerated at doses up to 600 mg/day.".
- Q5039678 atcPrefix "N03".
- Q5039678 atcSuffix "AX19".
- Q5039678 casNumber "194085-75-1".
- Q5039678 fdaUniiCode "P7725I9V3Z".
- Q5039678 iupacName "(S)-2-O-carbamoyl-1-o-chlorophenyl-ethanol".
- Q5039678 pubchem "9942577".
- Q5039678 thumbnail Carisbamate2DACS.svg?width=300.
- Q5039678 wikiPageWikiLink Q1368197.
- Q5039678 wikiPageWikiLink Q18924462.
- Q5039678 wikiPageWikiLink Q204711.
- Q5039678 wikiPageWikiLink Q3271540.
- Q5039678 wikiPageWikiLink Q333718.
- Q5039678 wikiPageWikiLink Q494158.
- Q5039678 wikiPageWikiLink Q576618.
- Q5039678 wikiPageWikiLink Q5920511.
- Q5039678 wikiPageWikiLink Q6268163.
- Q5039678 wikiPageWikiLink Q7108202.
- Q5039678 wikiPageWikiLink Q8567712.
- Q5039678 wikiPageWikiLink Q8788974.
- Q5039678 wikiPageWikiLink Q8919936.
- Q5039678 atcPrefix "N03".
- Q5039678 atcSuffix "AX19".
- Q5039678 casNumber "194085".
- Q5039678 iupacName "-2".
- Q5039678 pubchem "9942577".
- Q5039678 unii "P7725I9V3Z".
- Q5039678 type ChemicalSubstance.
- Q5039678 type Drug.
- Q5039678 type ChemicalObject.
- Q5039678 type Thing.
- Q5039678 type Q8386.
- Q5039678 comment "Carisbamate (YKP 509, proposed trade name Comfyde) is an experimental anticonvulsant drug under development by Johnson & Johnson Pharmaceutical Research and Development. In 1998, the compound was in-licensed from SK Corp. (currently Life Science Business Division of SK Holdings), a South Korean company. A phase II clinical trial in the treatment of partial seizures demonstrated that the compound has efficacy in the treatment of partial seizures and a good safety profile.".
- Q5039678 label "Carisbamate".
- Q5039678 depiction Carisbamate2DACS.svg.